NCT04850638已完成1 期
Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
The purpose of this study was to evaluate the effect of SHR4640 tablets on the pharmacokinetics of furosemide tablets in healthy male volunteers, using a single-center, single-arm, open, self-control design.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Voluntarily sign the informed consent form before the start of the activities related to this trial, and be able to understand the procedures and methods of this trial, and be willing to strictly abide by the clinical trial plan to complete this trial;
- •Adult males aged between 18 and 45 (including both ends, whichever is the time of signing the informed consent form);
- •Body weight ≥ 50kg and body mass index (BMI): 19~26kg/m2 (including both ends).
排除标准
- •Have a fertility plan or refuse to use medically approved contraceptives within 1 month from the screening period to the last medication;
- •Smokers (those who smoke more than 5 cigarettes per day on average);
- •During the first month of screening, the average daily alcohol intake was more than 25g (for example, 750mL beer, 250mL wine, or 50mL liquor) or those who were positive for alcohol in blood test or alcohol breath test during screening;
- •Those who have eaten grapefruit or its fruit juice products, any caffeine (such as coffee, tea, chocolate, cola or other caffeinated carbonated drinks, etc.), alcoholic food or beverages within 2 days before administration;
- •Drug abusers or those who were positive in urine drug test during screening;
- •The researchers judged that the subjects had medical conditions that affected the absorption, distribution, metabolism and excretion of drugs or reduced compliance
- •Any clinical history of serious illness or any disease or condition that the researchers believe may affect the results of the trial, including, but not limited to, a history of circulatory, endocrine, nervous system, digestive, urinary or blood, immune, mental and metabolic diseases;
- •Allergic constitution, or allergic to any ingredient in SHR4640 and furosemide tablets, or allergic to sulfonamides or thiazide diuretics, or allergic to any food ingredient, or having special dietary requirements, unable to follow a uniform diet;
- •Previous history of urinary diseases (such as benign prostatic hyperplasia, urinary tract stenosis) or other diseases that lead to dysuria;
- •Screen those who have undergone any operation within the first 3 months, or who have not recovered after the operation, or who may have a plan for operation or hospitalization during the trial;
- •Those who donated blood (or lost blood) and donated blood (or lost blood) ≥ 400 mL within 3 months before screening, or received blood transfusion;
- •During screening, physical examination, vital signs, laboratory examination (whole blood cell analysis, blood biochemical analysis, blood electrolyte examination, urine analysis, fasting blood lipids, thyroid function), 12-lead ECG, X-chest X-ray and abdominal B-ultrasound were abnormal and had clinical significance.
- •When screening, systolic blood pressure was less than 90mmHg or greater than 140mmHg, and / or diastolic blood pressure was less than 60mmHg or greater than 90mmHg;
- •Urinary system ultrasound suggested or suspected urinary system crystals or stones during screening;
- •Those whose serum uric acid was higher than 420 μ mol / L or had a previous history of hyperuricemia and / or gout;
- •The level of serum potassium was lower than that of 4.0mmol/L during screening.
- •According to the serum creatinine within 2 weeks before administration, the glomerular filtration rate ((estimated glomerular filtration rate, eGFR) calculated by the simplified kidney disease diet adjustment (modification of diet in renal disease, MDRD) formula (Annex 1) is less than 90 mL/min/1.73 m ².
- •Those who were positive for hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody, or syphilis antibody within one month before the screening;
- •Screening people who have participated in any drug or medical device clinical trial within the previous 3 months (subject to signing informed consent);
- •Used any prescription drugs, over-the-counter drugs, Chinese herbal medicines or dietary supplements within 2 weeks before screening.
研究组 & 干预措施
SHR4640 tablets
Experimental
干预措施: SHR4640 tablets and furosemide tablets (Drug)
结局指标
主要结局
Cmax
时间窗: Day1 to Day10
Peak plasma concentration
CLr
时间窗: Day1 to Day10
Renal Clearance
AUC0-t
时间窗: Day1 to Day10
Area under the curve from the time of dosing. Dosing time to the last measurable (positive) concentration.
AUC0-inf (if available)
时间窗: Day1 to Day10
Area under the curve from time 0 to infinity
Ae
时间窗: Day1 to Day10
Cumulative Amount of excretion
次要结局
- Tmax(Day1 to Day10)
- Vz/F(Day1 to Day10)
- t1/2(Day1 to Day10)
- CL/F(Day1 to Day10)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With GoutGoutNCT03131583Jiangsu HengRui Medicine Co., Ltd.15
已完成
1 期
Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy SubjectsHyperuricemiaNCT05954169Jiangsu HengRui Medicine Co., Ltd.16
Unknown
1 期
Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic ImpairmentHepatic ImpairmentNCT04305392Jiangsu HengRui Medicine Co., Ltd.24
已完成
1 期
PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT IntervalGout and HyperuricemiaNCT06196580Jiangsu HengRui Medicine Co., Ltd.24
已完成
1 期
Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy SubjectsHyperuricemiaNCT06168929Jiangsu HengRui Medicine Co., Ltd.34